Skip to main content

Table 2 Antibiotic consumption in the septic ward during quarters 1/2013 to 2/2016

From: Management of a cluster of Clostridium difficile infections among patients with osteoarticular infections

  Antibiotic consumption (DDD/100 hospital bed days) p a
2013 2014 2015 2016
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Narrow spectrum penicillinsb 8.8 20.8 16.5 26.3 6.8 11.3 8.3 15.0 26.5 19.6 13.0 34.8 35.0 52.0 0.131
Amino penicillin/BLI 7.8 3.2 0.5 1.8 6.4 4.1 15.4 4.3 7.2 10.9 16.7 16.3 10.0 7.2 0.044
Broad spectrum penicillinsc 2.7 1.0 1.6 0.0 2.4 3.4 5.2 2.0 4.5 2.3 8.2 4.5 3.5 5.1 0.046
Cephalosprins 1st and 2nd gen. 12.2 27.2 42.3 32.3 35.5 43.3 23.0 30.5 21.5 32.8 22.2 23.0 14.0 23.5 0.016
Cephalosprins 3rd gen. 2.1 3.2 2.1 2.4 4.1 3.7 0.8 1.5 0.9 0.6 1.7 0.0 1.8 0.0 0.015
Carbapenems 4.8 3.2 5.1 2.7 7.9 3.0 4.9 5.9 3.4 5.0 5.1 10.0 2.4 6.8 0.283
Fluoroquinolones 49.7 35.0 29.7 21.6 32.6 45.1 34.3 32.0 33.6 31.2 26.0 6.6 4.3 10.6 0.006
Clindamycin 9.1 12.1 19.3 0.0 12.3 25.2 19.4 12.6 22.1 15.2 6.8 3.7 4.4 5.1 0.001
Linezolid 2.4 3.2 4.4 2.4 4.0 3.6 3.5 2.0 2.8 7.9 4.8 6.9 8.7 10.1 0.019
Glycopeptide/daptomycin 5.4 5.9 5.7 1.5 6.2 4.5 4.6 3.8 5.1 3.6 4.8 8.9 5.4 13.8 0.143
Rifampicin 18.3 14.1 19.2 0.4 9.7 9.9 0.0 0.0 3.5 10.1 4.5 17.8 12.2 13.9 0.243
Total 125.6 132.3 150.6 106.9 129.7 157.3 122.7 113.1 133.0 141.6 122.1 133.5 103.5 150.2 0.348
  1. aComparision of average antibiotic consumption before (Q1/213-Q2/2015) and after (Q3/2105-Q2/2016) implementation of an intensified antibiotic stewardship program. bnarrow spectrum penicliins: penicillin G, flucloxacillin, aminopenicillins, c broad spectrum penicillins: piperacillin, piperacillin/tazobactam aminopenicillins